Key Points:

• LYC Healthcare has increased the proposed size of its Nasdaq IPO to approximately $25 million by offering 6.3 million shares at $4 each.
• The Singapore-based specialist healthcare provider previously planned to offer 3 million shares at $4 to $6, making the revised structure substantially larger while setting the proposed price at the bottom of its earlier range.
• The IPO would value LYC Healthcare at approximately $137 million and give investors exposure to an integrated musculoskeletal healthcare platform serving Singapore’s specialist medical market.

LYC Healthcare, a Singapore-based operator of healthcare clinics and orthopedic surgery centers, has increased the proposed size of its upcoming US IPO while lowering the proposed offering price. The company now plans to raise approximately $25 million through the sale of 6.3 million shares at $4 each, compared with its previous plan to offer 3 million shares at $4 to $6. The revised structure gives the company a larger potential capital raise while placing its proposed valuation at approximately $137 million.

Company Background and Business Model

Founded in 2017, LYC Healthcare is a multidisciplinary specialist healthcare provider focused on musculoskeletal services in Singapore. The company operates through two subsidiaries and five medical clinics, supported by in-house advanced imaging facilities. Its model integrates healthcare services across the patient journey, from health screenings and diagnostic imaging through specialist treatment, orthopedic procedures and rehabilitation.

LYC Healthcare has four doctors, including two specialists, and provides computer-navigated total hip and knee replacements as well as keyhole and minimally invasive procedures. Its diagnostic capabilities include MRI, CT, X-ray, bone mineral density and ultrasound imaging, while on-site physiotherapy is provided through a three-year collaboration. The company treats patients with degenerative joint diseases, spine conditions, sports injuries, metabolic diseases and osteoporosis. It generated approximately $14 million in revenue for the 12 months ended March 31, 2025.

IPO Details and Proposed Market Debut

Under the revised IPO structure, LYC Healthcare intends to offer 6.3 million shares at $4 per share, targeting approximately $25 million in gross proceeds. Its earlier filing contemplated 3 million shares at a price range of $4 to $6. At the revised deal size, the company is expected to command a market capitalization of approximately $137 million.

LYC Healthcare plans to list its shares on the Nasdaq, although it has not yet selected a final ticker symbol. Renaissance Capital currently identifies the company under the research ticker LYCH.RC. Pacific Century Securities is serving as the sole bookrunner, replacing AC Sunshine Securities. The larger share offering increases the potential amount of capital available to the company, while the $4 proposed price places the deal at the lower end of its previously indicated range.

Market Context and Growth Opportunities

The proposed market debut comes as investors continue to evaluate specialist healthcare businesses capable of combining clinical services, diagnostics and procedural care within a single platform. LYC Healthcare’s focus on musculoskeletal conditions positions it within a segment supported by demand for orthopedic treatment, diagnostic imaging and rehabilitation services. Its integrated model could also allow the company to capture revenue across multiple stages of patient care rather than relying on a single medical service.

For international investors, a Nasdaq listing could provide greater visibility for a Singapore-focused healthcare operator while giving LYC Healthcare access to US public-market capital. The expanded IPO also gives the company a larger financing opportunity to support its development, although the information provided does not specify how the proceeds will be allocated.

Risks and Investor Considerations

The IPO nevertheless carries several risks. LYC Healthcare operates in a competitive healthcare environment and must manage regulatory requirements, specialist staffing needs and the capital intensity associated with medical facilities and advanced imaging equipment. Its relatively modest revenue base also means investors will likely focus closely on its ability to achieve operating scale and translate its integrated model into sustainable profitability.

The increase in shares offered represents a meaningful change in the IPO structure and gives LYC Healthcare a larger fundraising target ahead of its potential Nasdaq market debut. Whether the offering attracts strong investor interest will depend on the company’s ability to demonstrate scalable growth, disciplined execution and a credible path toward stronger financial performance. For investors, the central question is whether LYC Healthcare can use its US listing and expanded capital raise to establish a differentiated position in Singapore’s specialist healthcare market, rather than simply becoming another small-cap IPO seeking access to public-market funding.